Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Kristen Treleven

Podiatrist, Primary Podiatric Medicine Greeley, CO Doctor of Podiatric Medicine

NPI 1558925362 CMS profile 8802282

1600 23Rd Ave, Greeley, CO 80634

Open in the dashboard

General payments

$7,145

90 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristen Treleven of Greeley, CO is reported in the CMS Open Payments database as having received $7,145 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,428 37
2024 General $559 13
2023 General $867 24
2022 General $901 6
2021 General $346 7
2020 General $3,044 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristen Treleven
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Kristen Treleven were reported at $1,428. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Kristen Treleven Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $0 $166 $51–$513 $163
2020 $3,044 $108 $33–$249 $114
2021 $346 $147 $52–$377 $132
2022 $901 $188 $66–$551 $149
2023 $867 $195 $70–$509 $160
2024 $559 $209 $59–$508 $164
2025 $1,428 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Gemini Mountain Medical, LLC $2,939 2 payments
  2. Paragon 28, Inc. $888 3 payments
  3. Smith+Nephew, Inc. $796 15 payments
  4. Treace Medical Concepts, Inc. $766 17 payments
  5. Horizon Therapeutics plc $266 2 payments
  6. Pylant Medical $213 3 payments
  7. Averitas Pharma Inc. $170 2 payments
  8. Orthofix Medical, Inc. $158 18 payments
  9. Osteoremedies, LLC $153 1 payment
  10. Amgen Inc. $152 5 payments
  11. Other $644 22 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,875 87 payments
  2. Education $2,939 2 payments
  3. Travel and Lodging $332 1 payment
Products named General payments · program years 2020–2025
  1. Product Portfolio $739 2 payments
  2. STRAVIX $394 5 payments
  3. TMC NANOPLASTY SYSTEM $322 4 payments
  4. KRYSTEXXA Krystexxa $266 2 payments
  5. LAPIPLASTY SYSTEM $201 4 payments
  6. Physio-Stim $182 19 payments
  7. Qutenza $170 2 payments
  8. BlastX $153 1 payment
  9. XPERIENCE $153 1 payment
  10. KRYSTEXXA Inflammation/Rare Disease $152 5 payments
  11. Other $1,909 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

255

Median for Podiatry: 160

Drug cost

$14,239

Median for Podiatry: $2,368

Branded share of claims

91.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 16 $10,012
Ciclopirox Ciclopirox Olamine Brand 166 $3,333
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 51 $463
Betamethasone Valerate Generic 22 $430

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$77,616

Of which drugs: $109

Medicare patients

265

Average age 77

Services billed

1,526

146 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 43%
Ischemic heart disease 40%
Chronic kidney disease 39%
Depression 29%
Atrial fibrillation 25%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 140 $104
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 56 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $152
$152 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $129
$129 — —
Qutenza
  • Averitas Pharma Inc. $30
$30 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record